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We  placed  isoﬂurane,  a general  anaesthetic,  inside  palmitoyloleoylphosphatidylcholine  (POPC)  bilay-n ﬁnal form 31 July 2015
vailable online 17 August 2015
ers  at  clinical  concentration,  and  performed  molecular  dynamics  simulations  at atmospheric  and  raised
pressures,  using  two  different  thermodynamic  ensembles.  We  also  performed  a simulation  of this system
with isoﬂurane  at ten times  the clinical  concentration.  We found  that isoﬂurane  did  not  aggregate  inside
POPC  membranes  at  20 MPa,  nor at 40 MPa.  The  implications  of these  ﬁndings  for pressure  reversal  is
discussed,  in  light  of  the high-pressure  neurological  syndrome.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
General anaesthetics (GAs) have been used for over 170 years,
nd literally millions of surgical operations have been performed
sing these drugs, but their site and mechanism of action are
till not entirely clear. In the beginning of the 20th century,
eyer [1] and Overton [2] proposed what is now known as the
eyer–Overton rule, which stated that the logarithm of the efﬁ-
acy of an anaesthetic was proportional to the logarithm of its
ipophilicity. Since this rule applied to a large variety of general
naesthetics, it suggested that a uniﬁed mechanism of action might
xist.
Half a century later, Johnson and Flagler [3,4] discovered the
henomenon of pressure reversal. They found that, by increasing
mbient pressure to between 2000 psi and 3000 psi (1.4 × 107 Pa
nd 2.1 × 107 Pa), general anaesthesia by ethanol could be reversed
n tadpoles. Paton and his co-workers [5,6], and Halsey and
ardley-Smith [7] extended the work by using several different
naesthetics and different animals, and the reversal phenomena
ere observed in all the general anaesthetics they used. The
ressure where pressure reversal was observed depended on
he species and the drug administered, and varied from 80 atm
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(8 × 106 Pa) [3] to 200 atm (2 × 107 Pa) [6]. This pressure reversal
effect has since been observed in many species and using different
kinds of general anaesthetics [8,9].
Subsequently, Trudell et al. [10,11] measured the electron
spin resonance spectra of spin-labelled phosphatidylcholine and
halothane solutions. They attached a nitroxide group to the termi-
nal methyl of the lipid tails, and measured the angular deviation of
the nitroxide 2p orbital axis from the axis of magnetic symme-
try. They deﬁned a bond order parameter S′n based on the angular
deviation, and found that applying halothane decreased S′n but
increasing pressure would increase S′n. These results implied that
the phospholipid cell membrane was involved in general anaes-
thetic action. Later, Cantor [12] suggested that drugs could induce
pressure change in the lipid membrane; these changes would shift
the conformational equilibrium of membrane proteins and thus
cause anaesthesia [13]. Scientists have certainly observed the effect
of membrane on ion channel gating [14], but there still is a debate
about the relative contributions of the membrane and the protein
to general anaesthetic effects [15].
Griepernau and Böckmann [16] investigated the links between
protein conformations and pressure changes by molecular dynam-
ics (MD) simulations. They used 1-alkanols as anaesthetics and
hydrated dimyristoylphosphatidylcholine (DMPC) bilayer as the
model cell membrane. By comparing the lateral pressure proﬁles of
systems at 105 Pa and 108 Pa, they found no signiﬁcant changes in
the protein conformational equilibrium unless the bent helix model
was assumed.
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Figure 1. Diagram showing a chemical diagram of isoﬂurane, with the C2
atom labelled (top panel), and the simulated system with 512 POPC molecules
(bottom panel). In the bottom panel, the atoms are coloured according to
this scheme: grey = carbon, white = hydrogen, blue = nitrogen, red = oxygen and
orange = phosphorus; all atoms of the isoﬂurane molecules are shown in cyan. In
the centre of the simulation box lie POPC molecules, with water molecules on either
side. The directions of the three axes are shown on the left; the xy-plane, where z = 0,J.R. Wieteska et al. / Chemical 
Unfortunately, at 108 Pa, pressure reversal is reversed; that is,
he general anaesthetics would be able to exert their anaesthetic
ffects if the animal were to survive pressures of that magnitude.
ohnson and Flagler [3,4] observed that non-anaesthetised tadpoles
wimming in a tank would increase their activity if exposed to a
ressure of between 1500 psi and 2500 psi (107 Pa to 1.7 × 107 Pa),
ut at about 4500 psi (3.1 × 107 Pa), their normal swimming move-
ents were replaced by uncoordinated twitches and spasms. For
on-anaesthetised newts, the increased activity was observed at
000 psi (6.9 × 106 Pa). In the presence of general anaesthetics, tad-
oles became active at between 2000 psi and 3000 psi (1.4 × 107 Pa
nd 2.1 × 107 Pa), but at about 3.1 × 107 Pa, they would exhibit simi-
ar uncoordinated muscle movements. However, this kind of spastic
aralysis was  always preceded by a brief restoration of swimming
ctivity. When these tadpoles were returned to atmospheric pres-
ure, most of them died within two days of the experiment, so
he spastic paralysis at 4500 psi (3.1 × 107 Pa) could be a prelude
o death. When this experiment was repeated on newts, the same
ehaviour was observed over a similar pressure range, but very few
f the animals died.
In the work of Lever et al. [5], in the absence of anaesthetics,
ore and more of the newts became paralysed as the pressure
ncreased, reaching 90% at 200 atm (2 × 107 Pa). In the presence
f anaesthetics, more than 90% of the newts were paralysed at
.4 × 106 Pa, but their activity increased as the pressure was  raised.
 maximum of 90% of the newts exhibited activity at a pressure
f about 1.3 × 107 Pa. There was then a drop in the activity level,
ut even at about 2.7 × 107 Pa, the activity level was over 50%.
his contrasts with the non-anaesthetised cases, where there was
o activity beyond 2 × 107 Pa. These authors did not report the
ost-experiment survival of these animals. The paralysis at around
.7 × 107 Pa remains a mystery, but no experimental work at that
ressure has been attempted again.
Recently, Chau et al. [17,18] performed molecular dynamics
imulations of a membrane patch with a concentration of halothane
ix times that of clinical concentration, and showed that the drugs
ggregated inside the membrane at raised pressures. In a sub-
equent simulation system [19], the concentration of halothane
sed was only twice that of clinical concentration; they were
ble to show that there was aggregation at 2 × 107 Pa but not
t 4 × 107 Pa. These results suggested that the aggregation of
alothane in the membrane at high pressure could be the mecha-
ism for pressure reversal and for the reversal of pressure reversal
escribed previously [3,5]. To generalise this conclusion, we carry
ut simulations on another general anaesthetic, isoﬂurane (1,1,1-
riﬂuoro-2-chloro-2-(diﬂuoromethoxy)-ethane), to determine if it
ehaves similarly to halothane in membranes at high pressures.
. Methods
.1. Molecular dynamics simulations
All molecular dynamics simulations were performed using
AMD version 2 [20], using the CHARMM36 potential [21] for
he membrane, the TIP3P potential [22] for water, and a special
otential for isoﬂurane [23]. The initial conﬁguration of hydrated
OPC membrane came from the CHARMM membrane builder freely
vailable on the internet. This system, under periodic boundary
onditions, contains 512 POPC molecules and is fully hydrated with
6691 water molecules, 44 potassium ions and 44 chloride ions,
iving a KCl solution of 0.14 M.  It is thereafter called the ‘pure POPC’
ystem. In a different system, nineteen isoﬂurane molecules were
dded to the membrane system, resulting in clinical concentration
f the drug (see appendix for details of how this was  determined).
he isoﬂurane molecules were placed randomly in the simulationis  between the two halves of the membrane. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
box, one by one, using an internal function of NAMD. The simula-
tion box was equilibrated to give an isotropic pressure proﬁle; this
system is thereafter referred to as the ‘POPC–isoﬂurane’ system. See
Figure 1 for a diagram showing isoﬂurane and the POPC–isoﬂurane
system.
Molecular dynamics simulations were carried out with
timesteps of 2 fs, at a temperature of 310 K and at pressures of,
respectively, 105 Pa (1 atm), 2 × 107 Pa (200 atm) and 4 × 107 Pa
(400 atm). Langevin dynamics was  applied; the thermostat was set
with a time constant of 5 ps−1, and the barostat set with a piston
decay time of 100 fs and a piston period of 200 fs. The van der Waals
cut-off was  13 A˚, and Ewald summation was applied to electrostat-
ics interactions. These NPT simulations were equilibrated for 60 ns
and data collection carried out for 100 ns. This set of simulations
will be called the NPT simulations.
In order to eliminate the effect of the thermostat and barostat
on aggregation, we calculated the average box size from the NPT
simulations, and used them to carry out simulations in the NVE
ensemble at pressures of, respectively, 105 Pa (1 atm), 2 × 107 Pa
(200 atm) and 4 × 107 Pa (400 atm), for 100 ns of simulated time.
This set of simulations will be called the NVE simulations.
Lastly, to investigate the effect of concentration on aggregation,
we also prepared a system consisting of 64 POPC molecules (fully
hydrated with 1856 water molecules) with 24 isoﬂurane molecules
embedded. This represents a system with ten times the clinical con-
centration of isoﬂurane. The system was equilibrated for 90 ns, and
a data-production run of 50 ns was carried out. Langevin dynam-
ics was applied; the thermostat was set with a time constant of
118 J.R. Wieteska et al. / Chemical Physics Letters 638 (2015) 116–121
Table 1
This table shows the thermodynamic properties of each system.
System E P T
512-POPC systems
Pure POPC −3.68 × 105 ± 1250 5.56 ± 121 310 ± 0.80
NPT 105 Pa −3.72 × 105 ± 1550 −0.260 ± 193 310 ± 0.85
NPT 2 × 107 Pa −3.72 × 105 ± 1550 202 ± 132 310 ± 0.85
NPT 4 × 107 Pa −3.75 × 105 ± 1550 405 ± 133 311 ± 0.86
NVE 105 Pa −3.68 × 105 ± 88 64.3 ± 125 310 ± 0.66
NVE 2 × 107 Pa −3.70 × 105 ± 88 282 ± 125 310 ± 0.66
NVE 4 × 107 Pa −3.73 × 105 ± 71 487 ± 126 310 ± 0.65
64-POPC system
NPT 105 Pa −3.30 × 104 ± 523 4.84 ± 378 310 ± 2.34
NPT 2 × 107 Pa −3.33 × 104 ± 523 207 ± 381 310 ± 2.41
NPT 4 × 107 Pa −3.52 × 104 ± 594 398 ± 383 310 ± 2.54
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Figure 2. Diagram showing the atomic density distribution along the z-axis, (z), of
the  choline nitrogen of the POPC molecules, and that of the carbon atom of halothane.
The  distribution of the choline nitrogen is not affected by the change in pressure,
so we show only one set of data. The distribution of halothane carbon atoms are
shown for the three different pressures, colour-coded as in the legend. The values
for  nitrogen have been divided by 512 so that the four lines can be viewed on the
pressures. The second maximum is centred around r = 10.5A˚; g(r)
is about 3 when the pressure is 2 × 107 Pa, but drops to about 1.7
when the pressure is 4 × 107 Pa.
1
2
3
4
5
g(
r)
g(r) of isoflurane C2 in 512 POPC : NPT 100 ns data
p = 105Pa
p = 2.107Pa
p = 4.107Pa = total energy (kJ/mol), P = pressure (105 Pa), T = temperature (K).
.01 ps−1, and the barostat set with a piston decay time of 250 ps
nd a piston period of 500 ps. The van der Waals cut-off was  13 A˚,
nd Ewald summation was applied to electrostatics interactions.
his set of simulations will be called the high-concentration simu-
ations.
.2. Deuterium order parameter
Order parameters give us the information about the structure
f the phospholipids of membranes. In this work, we use the deu-
erium order parameter SCD, which is deﬁned in the following
anner: the SCD of a given carbon atom of the lipid tail can be
alculated as:
CD = −
〈3cos2 − 1〉
2
(1)
here  is the angle between the C H bond and the membrane nor-
al, and the term in angled brackets denote ensemble averaging
ver all the membrane molecules, over the C atoms located at the
ame position in the two tails, and over both C H bonds belong-
ng to the same C atom. The deuterium order parameter measures
oughly the same quantity as the order parameter used by Trudell
t al. [10].
. Results
.1. Energy, temperature and pressure
Table 1 shows the thermodynamic properties of the systems.
he energy and temperature are stable. The ﬂuctuation of pressure
s large due to the small size of the simulation box, which is typical
or simulations of this scale.
In our simulations, the area per POPC molecule is 64.6 A˚2 ± 0.1A˚2
t 105 Pa and 63.8 A˚2 ± 0.1 A˚2 at 4 × 107 Pa. Previous experiments
howed that, in the liquid phase (L˛ phase), the area per POPC
olecule was 63 A˚2 at 297 K [24], 68.3 A˚ at 303 K [25], 66 A˚2 at 310 K
26], and 62 A˚2 at 323 K [27]. Our system is thus in the biologically
elevant liquid phase at all pressures. These results are also con-
istent with experimental ﬁndings that, at a pressure of 4 × 107 Pa,
he gel/liquid phase transition temperature of POPC is about 278 K
28], well below our simulation temperature of 310 K.
We also show the distribution of the isoﬂurane molecules in the
-direction in Figure 2. The isoﬂurane molecules are preferentially
ocated near the headgroup, with a small number of them located
n the lipid matrix. These results are consistent with those from
revious work [19].same graph. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
3.2. Radial distribution function g(r)
The radial distribution function between the C2 atom of
isoﬂurane molecules, g(r), are shown in Figures 3, 4 and 5,
respectively, for the NPT simulation, the NVE simulation and the
high-concentration simulation. The average and standard devia-
tion were calculated. We  take the C2 atom because it is the atom
nearest the centre of mass of isoﬂurane.
For the NPT simulation, the ﬁrst maxima of the g(r) at the three
pressures are indistinguishable from each other, though there are
some differences in the second maximum. The ﬁrst maxima all
reach a value of about 4.0 when r = 6 A˚. The ﬁrst minimum is at
r = 8.5 A˚ with a g(r) of 1.5, and is almost identical for all three100 20
r / Å
0
Figure 3. Diagram showing the radial distribution function of the C2 atom of isoﬂu-
rane in the molecular dynamics simulation runs performed with an NPT ensemble.
The concentration of isoﬂurane used is that of clinical concentration.
J.R. Wieteska et al. / Chemical Physics Letters 638 (2015) 116–121 119
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r / Å
0
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g(
r)
g(r) of isoflurane C2 in 512 POPC : NVE, 100 ns data
p = 105Pa
p = 2.107Pa
p = 4.107Pa
Figure 4. Diagram showing the radial distribution function of the C2 atom of isoﬂu-
rane in the molecular dynamics simulation runs performed with an NVE ensemble.
The  concentration of isoﬂurane used is that of clinical concentration.
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r / Å
0
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g(
r)
g(r) of isoflurane C2 in 512 POPC : NPT, 41ns − 50ns
p = 105Pa
p = 2.107Pa
Figure 6. Diagram showing the radial distribution function of the C2 atom of isoﬂu-For the NVE simulation, at 105 Pa, the ﬁrst maximum is about 3,
nd it decreases to 2.0 at 2 × 107 Pa, and is about 1.5 at 4 × 107 Pa.
he ﬁrst minimum is at r = 8.2 A˚ with a g(r) of <1, and is almost
dentical for all three pressures. The second maximum is also at
 = 10.5 A˚, but its magnitude at different pressures is almost identi-
al. There is then a second minimum at r = 13 A˚; it is more obvious
t 2 × 107 Pa than at other pressures.
For the high-concentration simulation, the g(r) at all three
ressures are very close to each other. There is a ﬁrst maximum
f about 2.5 at r = 6 A˚, then a ﬁrst minimum of about 1.0 at r = 8.5 A˚,
 second maximum of about 1.5 at about r = 10.7 A˚ and a second
inimum of 1.1 at r = 13 A˚.
We can thus conclude that no aggregation of isoﬂurane
olecules is observed at 2 × 107 Pa. Using the NPT ensemble, the
(r) graphs at all three pressures are quite similar; using the NVE
nsemble, there is a monotonic decrease in the ﬁrst maximum of
he g(r) as the pressure increases. In both simulations, there are
arge ﬂuctuations in the g(r) graphs (data not shown).100 20
r / Å
0
1
2
3
4
g(
r)
g(r) of 64 hydrated POPC + 24 isoflurane, 50 ns
p = 105Pa
p = 2.107Pa
p = 4.107Pa
igure 5. Diagram showing the radial distribution function of the C2 atom of isoﬂu-
ane in the molecular dynamics simulation runs performed with an NPT ensemble.
he concentration of isoﬂurane used is ten times that of clinical concentration.rane in the molecular dynamics simulation runs performed with an NPT ensemble,
between the 41st nanosecond to the 50th nanosecond, at two different pressures.
The concentration of isoﬂurane used is that of clinical concentration.
3.3. Number of unclustered molecules
Since we performed some of the simulations at clinical concen-
tration of isoﬂurane, we could proceed to quantify the number of
molecules in the membrane under different conditions.
We calculated the number of unclustered molecules at extremes
of aggregation. Figure 6 shows the g(r) of the isoﬂurane C2 atom at
105 Pa and at 2 × 107 Pa, between the 41st nanosecond and the 50th
nanosecond. It can be seen that there is a big difference between the
ﬁrst maxima at two pressures. We decided that the ﬁrst solvation
shell has a radius of 8 A˚. Using this value, we  evaluated the number
of unclustered molecules in the two system. At 105 Pa, this is 18.6,
and at 2 × 107 Pa, it is 17.0 (out of a total of 19 isoﬂurane molecules).
The same argument goes for the case of halothane. Although we
only performed simulations at twice the clinical concentration of
the drug [19], the difference in g(r) when halothane aggregated and
when it did not was similar to the difference observed for isoﬂurane.
Thus, even if we were to observe the degree of aggregation as
dramatic as that shown in Figure 6, this would constitute only a
reduction of the concentration of isoﬂurane by less than 10%. In
pharmacological terms, this is negligible; the effect of drugs is not
signiﬁcantly attenuated with a 10% reduction in concentration. This
was observed in the case of halothane, but not in isoﬂurane. It can
thus be safely concluded that the aggregation of general anaesthet-
ics inside the membrane is not a mechanism for pressure reversal.
3.4. Deuterium order parameter
Figure 7 shows a chemical diagram of POPC, with the location of
each corresponding bond number. Panel (b) shows that the bond-
order parameter at all three pressures is very similar, and that
the presence of isoﬂurane does not greatly change the bond order
parameter.
4. Discussion
Although general anaesthetics have been in use for over 160
years, their exact site and mechanism of action are still unclear.
Johnson and Flagler [3,4] showed that increased pressure reversed
anaesthesia, and this work has been repeated by many researchers
ever since [5–7].
Signiﬁcantly, Halsey and Wardley-Smith [7] showed that pres-
sure reverses the effect not only of general anaesthetics, but also
120 J.R. Wieteska et al. / Chemical Physics Letters 638 (2015) 116–121
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higure 7. The top panel shows the bond numbering scheme used in our calculation
OPC  only (POPC 105 Pa), and of POPC with isoﬂurane at three different pressures (
f other drugs such as diazepam, chlorpromazine and lignocaine,
nto their respective sites of action. Since the sites of action of
hlorpromazine and lignocaine are known to be different from
he putative site of action of general anaesthetics, it appears that
ressure reversal is a pharmacokinetic effect, rather than a phar-
acodynamic effect. Pharmacokinetics describes the processes
hereby a drug is absorbed, distributed and transported to its site
f action, so pharmacokinetic effects are not speciﬁc to any partic-
lar binding site. Pharmacodynamic effects are site-speciﬁc.
This possibility was supported by the ﬁnding that general anaes-
hetics were found to be enantiospeciﬁc, but this enantiospeciﬁcity
annot be accounted for by their effects on the cell membrane
29–32]. The membrane is thus unlikely to be the site of action
f general anaesthetics. The putative target protein of at least
he halogenated alkane general anaesthetics was postulated to be
he -aminobutyric acid type A receptor (GABAA receptor); it has
een shown that modifying the GABAA receptor would modify the
esponse to general anaesthetics in whole animals [33,34]. Muta-
ions of this receptor and subsequent patch-clamping of the protein
lso supported this hypothesis [35–37]. For a more detailed discus-
ion of the membrane hypothesis vs the protein hypothesis, please
ee Chau [15].
Jenkins et al. [38] noted that different general anaesthetics were
f different sizes; isoﬂurane is bigger than halothane, which in
urn is bigger than chloroform. They also noted that mutations of
he ˛-subunit transmembrane domain 2 amino acid Ser 270 could
bolish GABAA-receptor modulation by general anaesthetics. They
utated Ser 270 into amino acids of different sizes, and were able
o estimate the volume of a proposed anaesthetic binding site to
e 250 A˚3–370 A˚3. Their results also suggest that the sites of action
or isoﬂurane, halothane and chloroform at least has a signiﬁcant
egree of overlap; it is also probable that these drugs share a com-
on  binding site. This putative binding site is only large enough toccommodate one isoﬂurane molecule.
In previous work, we proposed that pressure reversal occurred
hen halothane aggregated, so there were fewer monomeric
alothane to bind to this putative binding site [17,19]. In this lower panel shows the bond order parameter of the system consisting of hydrated
5 Pa, iso 2 × 107 Pa and iso 4 × 107 Pa).
work, we performed simulations of nineteen isoﬂurane molecules
inside the POPC membrane at pressures of 105 Pa, 2 × 107 Pa and
4 × 107 Pa. The concentration of isoﬂurane used was  that of clinical
concentration or ten times that of clinical concentration. At clinical
concentration, we also tried two  different thermodynamic ensem-
bles. We  did not observe any isoﬂurane aggregation inside the POPC
membrane in the pressure ranges tested.
It is thus possible that pressure-induced aggregation is only
observed with the halothane-DMPC or halothane-POPC combina-
tion. In these cases, where aggregation was  observed, the halothane
g(r) graphs [19] showed the same trend as the isoﬂurane g(r) graph
shown in Figure 6, so a 10% reduction in free halothane would
be expected. In the case of isoﬂurane, we  quantiﬁed the reduc-
tion in unaggregated isoﬂurane in the membrane under transient
conditions where aggregation was  observed. In both cases, a 10%
reduction in free general anaesthetics is not enough to cause any
signiﬁcant reduction in drug effect. What other mechanism could
account for pressure reversal then?
High pressure causes hyperexcitability of the central nervous
system (see Halsey [39], Jain [40] for reviews on the effect of
high pressure on the central nervous system). The symptoms
include headache, vertigo, nausea, and euphoria; the patient
exhibits clinical signs such as tremor, opsoclonus, myoclonus,
dysmetria, hyperreﬂexia and, in experimental animals, convul-
sions. There are also cognitive deﬁcits and memory impairment.
Experiments on the baboon [41] show that a competitive NMDA
receptor antagonist can reduce body tremor and brain electro-
encephalogram changes, showing this receptor is involved in the
high-pressure neurological syndrome (HPNS). Experiments also
demonstrate the involvement of the neurotransmitter GABA in
the high-pressure neurological syndrome in the baboon [42].
Drugs such as ﬂurazepam or diaminobutyric acid, which enhanced
the activation of the GABAA receptor, substantially raised the
threshold for both tremor and convulsions [43]. It is now
thought that the change of balance between the noradrenaline,
dopamine, NMDA and GABA systems causes the HPNS disturbances
[44,45].
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[
[J.R. Wieteska et al. / Chemical 
Thus the key to pressure reversal may  lie in the GABAA receptor.
his receptor is most probably the target of a large number of gen-
ral anaesthetics [15], and it is also pivotal to some of the effects of
he high-pressure neurological syndrome. At raised pressures, the
ody experiences changes related to the high-pressure neurologi-
al syndrome. General anaesthetics have been shown to potentiate
he effect of GABA on its GABAA receptor [46]; they might well
ct like ﬂurazepam or diaminobutyric acid to increase the activity
f the GABAA receptor, and thus reduce the effects of the high-
ressure neurological syndrome.
If this hypothesis is true, then pressure reversal is a mani-
estation of the high-pressure neurological syndrome, masked by
naesthesia. We  would then expect general anaesthetics not to
bolish pressure effects completely, as some of the high-pressure
eurological syndrome effects are mediated by other neurotrans-
itter systems [44,47], and thus would be insensitive to general
naesthetics. We  would also expect mutations of the GABAA recep-
or which potentiate the effect of GABA to render the subject less
usceptible to pressure reversal, as it is protected against the high-
ressure neurological syndrome.
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ppendix A.
In the appendix, we determine the number of isoﬂurane
olecules to be put into each membrane.
The oil:gas partition coefﬁcient for isoﬂurane has been reported
o be 90.8 [48], or between 78 and 140 depending on the temper-
ture [49]. We  take the oil:gas partition coefﬁcient to be 100 for
soﬂurane. This means 1 l of lipids would contain 100 l of isoﬂurane
as if exposed to 100% isoﬂurane at a pressure of 105 Pa. How-
ver, the minimum alveolar concentration (MAC) of isoﬂurane for
naesthesia is 1.2% [50]. By Henry’s Law, 1 l of lipids contain 1.2 l
f isoﬂurane. At body temperature, 1 mol  of isoﬂurane occupies
bout 24 l of space. Thus the concentration of isoﬂurane in lipids
s 1.2 l/24 l = 0.05 mol.
We assume that the density of POPC is not far from that of water,
hen given its relative molecular mass of 760, 1 l of POPC contains
000/760 mol  of POPC, or about 1.32 mol  of POPC. Thus, at MAC,
isoﬂurane]/[POPC] = 0.05/1.32 = 0.038. This means for each POPC
olecule, there should be 0.038 isoﬂurane molecule. For 512 POPC,
t clinical concentration, there should be 19 isoﬂurane molecules.
t 10× the clinical concentration, for 64 POPC, there should be 24
soﬂurane molecules.
[
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